Jack Shi

1.9k citations

19 papers · 1.1k indexed · h-index 13

Biological Psychiatry top 2%
- Tryptophan and brain disorders 5
Genetics top 5%
- Myeloproliferative Neoplasms: Diagnosis and Treatment 4
Immunology top 10%
- Psoriasis: Treatment and Pathogenesis 3
Dermatology top 5%
- Dermatology and Skin Diseases 3
Hematology top 5%
- Chronic Myeloid Leukemia Treatments 3
Oncology
- Cytokine Signaling Pathways and Interactions 3
Psychiatry and Mental health
- Bipolar Disorder and Treatment 3
Pediatrics, Perinatology and Child Health
- Childhood Cancer Survivors' Quality of Life 2

Co-authors: Peggy Scherle Swamy Yeleswaram William V. Williams Naresh Punwani Xuejun Chen Thomas Emm Yvonne Lo Robert Newton
Cited by: Biological Psychiatry Genetics Immunology
Journals: The Journal of Clinical Pharmacology (7 papers)Journal of the American Academy of Dermatology (1 paper)Journal of Clinical Oncology (1 paper)
Partner nations: United States United Kingdom Russia

In The Last Decade

Jack Shi

18 papers receiving 1.1k citations

Peers

Countries citing papers authored by Jack Shi

Since Specialization

Citations

This map shows the geographic impact of Jack Shi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jack Shi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jack Shi more than expected).

Fields of papers citing papers by Jack Shi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jack Shi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jack Shi. The network helps show where Jack Shi may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Jack Shi, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Jack Shi Line = papers co-authored together Jack Shi links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

#	Work
1	Safety, pharmacokinetics and pharmacodynamics of Plozasiran in Chinese healthy volunteers Cardiovascular Diabetology ·Fangfang Wang,Cristina Dima,明美中尾,Jack Shi,Ye Li,Gazimzyan Sharafutdinov,Haiyan Li	2025	0
2	Population Pharmacokinetic Modeling of Subcutaneous Plozasiran in Healthy Volunteers and Patients with Familial Chylomicronemia Syndrome, Severe Hypertriglyceridemia, and Mixed Hyperlipidemia The Journal of Clinical Pharmacology ·James Ousey,Claudia Jomphe,Chaikledkaew U,Nathalie Gosselin,Jack Shi	2025	1
3	Population Pharmacokinetics and Pharmacodynamics of Burosumab in Adult and Pediatric Patients With X‐linked Hypophosphatemia The Journal of Clinical Pharmacology ·林智孟,Nathalie Gosselin,Julie Taylor,Mary Scott Roberts,Kathleen McKeever,Jack Shi	2021	6
4	The Pharmacokinetics of Triheptanoin and Its Metabolites in Healthy Subjects and Patients With Long‐Chain Fatty Acid Oxidation Disorders Clinical Pharmacology in Drug Development ·林智孟,杨晓雁,Jack Shi,Kathleen McKeever	2021	3
5	Pharmacokinetic and Pharmacodynamic Modeling to Optimize the Dose of Vestronidase Alfa, an Enzyme Replacement Therapy for Treatment of Patients with Mucopolysaccharidosis Type VII: Results from Three Trials Clinical Pharmacokinetics ·K. Barathi Raja,Kathleen McKeever,Julie Taylor,Christine Haller,Lawrence Jia,Simon Jones,Jack Shi	2018	19
6	A randomised, open-label, phase 2 study of the IDO1 inhibitor epacadostat (INCB024360) versus tamoxifen as therapy for biochemically recurrent (CA-125 relapse)–only epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube cancer Gynecologic Oncology ·Rebecca Kristeleit,Ірина Давиденко,Vadim Shirinkin,由理石丸,Igor Bondarenko,Michael J. Goodheart,В. А. Горбунова,C A Penning,Jack Shi,Xiangdong Liu,Robert Newton,Yufan Zhao,Janet Maleski,Lance Leopold,Russell J. Schilder	2017	78
7	In Vitro Interactions of Epacadostat and its Major Metabolites with Human Efflux and Uptake Transporters: Implications for Pharmacokinetics and Drug Interactions Drug Metabolism and Disposition ·Qiang Zhang,Yan Zhang,Jason Boer,Jack Shi,Peidi Hu,Sharon Diamond,Swamy Yeleswaram	2017	12
8	First-in-Human Phase I Study of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase-1 Epacadostat (INCB024360) in Patients with Advanced Solid Malignancies Clinical Cancer Research ·Gregory L. Beatty,Peter J. O’Dwyer,Jason Clark,Jack Shi,Kevin Bowman,Peggy Scherle,Robert Newton,Richard Schaub,Janet Maleski,Lance Leopold,Thomas F. Gajewski	2017	240
9	Population Pharmacokinetic and Pharmacodynamic Modeling of Epacadostat in Patients With Advanced Solid Malignancies The Journal of Clinical Pharmacology ·Jack Shi,Kevin Bowman,Xuejun Chen,Janet Maleski,Lance Leopold,Swamy Yeleswaram	2016	13
10	Potential Underprediction of Warfarin Drug Interaction From Conventional Interaction Studies and Risk Mitigation: A Case Study With Epacadostat, an IDO1 Inhibitor The Journal of Clinical Pharmacology ·Jack Shi,Xuejun Chen,Naresh Punwani,William V. Williams,Swamy Yeleswaram	2016	7
11	Downmodulation of key inflammatory cell markers with a topical Janus kinase 1/2 inhibitor British Journal of Dermatology ·Naresh Punwani,Timothy C. Burn,Peggy Scherle,輝美日比,Jack Shi,Paul Collier,Мусаев Э.Т.,Patrick J. Haley,Young Lo,Paul Waeltz,James D. Rodgers,Stacey Shepard,Kris Vaddi,Swamy Yeleswaram,Richard Levy,William V. Williams,Alice B. Gottlieb	2015	53
12	The pharmacokinetics, pharmacodynamics, and safety of baricitinib, an oral JAK 1/2 inhibitor, in healthy volunteers The Journal of Clinical Pharmacology ·Jack Shi,Xuejun Chen,Fiona Lee,Thomas Emm,Peggy Scherle,Yvonne Lo,Naresh Punwani,William V. Williams,Swamy Yeleswaram	2014	164
13	Pharmacokinetics and pharmacodynamics of orally administered ruxolitinib (INCB018424 phosphate) in renal and hepatic impairment patients Clinical Pharmacology in Drug Development ·Xuejun Chen,Jack Shi,Thomas Emm,Peggy Scherle,Ryan McGee,Yvonne Lo,Mahendra Kumar Das,Naresh Punwani,William V. Williams,Swamy Yeleswaram	2013	27
14	Phase I study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the oral inhibitor of indoleamine 2,3-dioxygenase (IDO1) INCB024360 in patients (pts) with advanced malignancies. Journal of Clinical Oncology ·Gregory L. Beatty,Peter J. O’Dwyer,Jason Clark,Jack Shi,Robert Newton,Richard Schaub,Janet Maleski,Lance Leopold,Thomas F. Gajewski	2013	34
15	Preliminary clinical activity of a topical JAK1/2 inhibitor in the treatment of psoriasis Journal of the American Academy of Dermatology ·Naresh Punwani,Peggy Scherle,Muhammed Rafi K K -,Jack Shi,Jinjin Liang,Swamy Yeleswaram,Richard Levy,William V. Williams,Alice B. Gottlieb	2012	148
16	The Pharmacokinetics, Pharmacodynamics, and Safety of Orally Dosed INCB018424 Phosphate in Healthy Volunteers The Journal of Clinical Pharmacology ·Jack Shi,Xuejun Chen,Ryan McGee,Mahendra Kumar Das,Thomas Emm,Yvonne Lo,Peggy Scherle,Naresh Punwani,William V. Williams,Swamy Yeleswaram	2011	123
17	Preclinical Evaluation of Local JAK1 and JAK2 Inhibition in Cutaneous Inflammation Journal of Investigative Dermatology ·Jordan S. Fridman,Peggy Scherle,Robert J. Collins,Timothy C. Burn,Brett A. Neilan,Мусаев Э.Т.,Nancy Contel,Patrick J. Haley,Beth Ann Thomas,Jack Shi,Paul Collier,James D. Rodgers,Stacey Shepard,Brian Metcalf,Gregory Hollis,Robert Newton,Swamy Yeleswaram,Steven Friedman,Kris Vaddi	2011	88
18	The Effect of CYP3A4 Inhibition or Induction on the Pharmacokinetics and Pharmacodynamics of Orally Administered Ruxolitinib (INCB018424 Phosphate) in Healthy Volunteers The Journal of Clinical Pharmacology ·Jack Shi,Xuejun Chen,Thomas Emm,Peggy Scherle,Ryan McGee,Yvonne Lo,Mahendra Kumar Das,Xinlan Zhang,Naresh Punwani,William V. Williams,Swamy Yeleswaram	2011	86
19	The relevance of assessment of intestinal P-gp inhibition using digoxin as an in vivo probe substrate Nature Reviews Drug Discovery ·Jack Shi,Yan Zhang,Swamy Yeleswaram	2010	22

About Jack Shi

Jack Shi is a scholar working on Biological Psychiatry, Genetics and Hematology, having authored 19 papers that have together received 1.1k indexed citations. Recurring topics across this work include Tryptophan and brain disorders (5 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (4 papers), Cytokine Signaling Pathways and Interactions (3 papers), Dermatology and Skin Diseases (3 papers), Chronic Myeloid Leukemia Treatments (3 papers), Bipolar Disorder and Treatment (3 papers), Psoriasis: Treatment and Pathogenesis (3 papers) and Childhood Cancer Survivors' Quality of Life (2 papers). The work is most often cited by research in Biological Psychiatry (181 citations), Genetics (228 citations) and Immunology (396 citations). Jack Shi has collaborated with scholars based in United States, United Kingdom and Russia. Frequent co-authors include Peggy Scherle, Swamy Yeleswaram, William V. Williams, Naresh Punwani, Xuejun Chen, Thomas Emm, Yvonne Lo, Robert Newton, Lance Leopold and Janet Maleski. Their work appears in journals such as The Journal of Clinical Pharmacology, Journal of the American Academy of Dermatology, Journal of Clinical Oncology, Clinical Cancer Research and British Journal of Dermatology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact